Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study.

Abstract

Results of a clinical trial which uses monotherapy with monoclonal anti-TNF alpha antibody in patients with rheumatoid arthritis failing standard treatment. Certolizumab was significantly more efficient than placebo.

Safety profile was comparable to other anti-TNF inhibitors.

Keywords

• certolizumab pegol monotherapy
• rheumatoid arthritis
• disease-modifying antirheumatic therapy
• FAST4WARD study